New therapies for chronic hepatitis B

Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment

(2015) Guo-Jun Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the “magic bullet” to kill cccDNA

(2015) Ejuan Zhang et al.   ANTIVIRAL RESEARCH

Chronic hepatitis B: A wave of new therapies on the horizon

(2015) Timothy M. Block et al.   ANTIVIRAL RESEARCH

The hepatitis B virus ribonuclease H as a drug target

(2015) John E. Tavis et al.   ANTIVIRAL RESEARCH

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities

(2015) Robert G. Gish et al.   ANTIVIRAL RESEARCH

Core protein: A pleiotropic keystone in the HBV lifecycle

(2015) Adam Zlotnick et al.   ANTIVIRAL RESEARCH

Host–virus interactions in hepatitis B virus infection

(2015) Luca G Guidotti et al.   CURRENT OPINION IN IMMUNOLOGY

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

(2015) S Zhen et al.   GENE THERAPY

Present and future therapies of hepatitis B: From discovery to cure

(2015) T. Jake Liang et al.   HEPATOLOGY

O115 : High antiviral activity of the HBV core inhibitor NVR 3-778 in the humanized uPA/SCID mouse model

(2015) K. Klumpp et al.   JOURNAL OF HEPATOLOGY

P0640 : Effect of the combination of the HBV core inhibitor NVR 3-778 with nucleoside analogs or other HBV core inhibitors on the inhibition of HBV DNA replication in HepG2.2.15 cells

(2015) A. Lam et al.   JOURNAL OF HEPATOLOGY

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection

(2015) Edward J. Gane et al.   JOURNAL OF HEPATOLOGY

Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B

(2015) Stephan Menne et al.   JOURNAL OF HEPATOLOGY

Early inhibition of hepatocyte innate responses by hepatitis B virus

(2015) Souphalone Luangsay et al.   JOURNAL OF HEPATOLOGY

In vivo genome editing using Staphylococcus aureus Cas9

(2015) F. Ann Ran et al.   NATURE

High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein

(2015) Klaus Klumpp et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease

(2015) Edward M. Kennedy et al.   VIROLOGY

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

(2015) Vyas Ramanan et al.   Scientific Reports

Does Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus Genome Repair?

(2015) Xiuji Cui et al.   PLoS One

STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus

(2014) Fang Guo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes

(2014) Stephan Urban et al.   GASTROENTEROLOGY

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN

(2014) H Fontaine et al.   GUT

Inhibitors of Hepatitis B Virus Attachment and Entry

(2014) Florian A. Lempp et al.   INTERVIROLOGY

HBV and the immune response

(2014) Carlo Ferrari   LIVER INTERNATIONAL

CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity

(2014) Rodolphe Barrangou et al.   MOLECULAR CELL

Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses

(2014) Christian Königer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA

(2014) J. Lucifora et al.   SCIENCE

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study

(2014) Anuj Gaggar et al.   VACCINE

Coinhibitory receptors and CD8 T cell exhaustion in chronic infections

(2014) Vijay K. Kuchroo et al.   Current Opinion in HIV and AIDS

Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection

(2014) Jia Liu et al.   PLoS Pathogens

The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo

(2014) Su-Ru Lin et al.   Molecular Therapy-Nucleic Acids

Targeting Hepatitis B Virus With CRISPR/Cas9

(2014) Christoph Seeger et al.   Molecular Therapy-Nucleic Acids

Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B

(2013) A. K. Singal et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Chronic hepatitis B: What should be the goal for new therapies?

(2013) Timothy M. Block et al.   ANTIVIRAL RESEARCH

Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into Hepatocytes

(2013) Yi Ni et al.   GASTROENTEROLOGY

Pathogen Recognition Receptors: Ligands and Signaling Pathways by Toll-Like Receptors

(2013) Miwa Sasai et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues

(2013) Geoffrey Dusheiko   LIVER INTERNATIONAL

Structural mechanism of cytosolic DNA sensing by cGAS

(2013) Filiz Civril et al.   NATURE

Augmentation of Hepatitis B Virus-Specific Cellular Immunity with Programmed Death Receptor-1/Programmed Death Receptor-L1 Blockade in Hepatitis B Virus and HIV/Hepatitis B Virus Coinfected Patients Treated with Adefovir

(2012) Amy C. Sherman et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation

(2012) Dawei Cai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

(2012) Tetsuya Hosaka et al.   HEPATOLOGY

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus

(2012) Tassilo Volz et al.   JOURNAL OF HEPATOLOGY

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

(2012) Huan Yan et al.   eLife

Review article: current antiviral therapy of chronic hepatitis B

(2011) W. S. Ayoub et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

(2011) Antonio Bertoletti et al.   GUT

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

(2010) E. Jenny Heathcote et al.   GASTROENTEROLOGY

Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

(2009) Patrick Marcellin et al.   GASTROENTEROLOGY

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

(2008) M J McKeage et al.   BRITISH JOURNAL OF CANCER

Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells

(2008) O. Hantz et al.   JOURNAL OF GENERAL VIROLOGY

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein

(2008) Joerg Petersen et al.   NATURE BIOTECHNOLOGY

Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

(2008) Patrick Marcellin et al.   NEW ENGLAND JOURNAL OF MEDICINE